ProVise Management Group LLC increased its holdings in Amrize Ltd (NYSE:AMRZ – Free Report) by 11.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 16,642 shares during the quarter. ProVise Management Group LLC’s holdings in Amrize were worth $6,145,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in Amrize during the 3rd quarter valued at about $49,000. Continuum Advisory LLC bought a new stake in shares of Amrize in the second quarter worth approximately $62,000. IFP Advisors Inc grew its stake in shares of Amrize by 1,707.3% in the third quarter. IFP Advisors Inc now owns 1,988 shares of the company’s stock worth $74,000 after acquiring an additional 1,878 shares during the period. NewEdge Advisors LLC grew its stake in shares of Amrize by 1,419.7% in the second quarter. NewEdge Advisors LLC now owns 2,082 shares of the company’s stock worth $111,000 after acquiring an additional 1,945 shares during the period. Finally, Oslo Pensjonsforsikring AS purchased a new position in shares of Amrize during the first quarter valued at approximately $133,000.
Insiders Place Their Bets
In other Amrize news, CEO Jan Jenisch acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was purchased at an average price of $42.50 per share, with a total value of $170,000.00. Following the transaction, the chief executive officer directly owned 519,000 shares in the company, valued at approximately $22,057,500. The trade was a 0.78% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jacques Sanche acquired 4,150 shares of Amrize stock in a transaction dated Wednesday, August 26th. The stock was bought at an average price of $45.02 per share, with a total value of $186,833.00. Following the completion of the purchase, the director directly owned 9,766 shares in the company, valued at $439,665.32. This represents a 73.90% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 34,155 shares of company stock valued at $1,461,276. Insiders own 0.54% of the company’s stock.
Amrize Stock Performance
AMRZ opened at $40.85 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. The company has a market cap of $22.59 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.60 and a beta of 0.03. The company’s 50 day moving average is $39.33 and its 200 day moving average is $49.98. Amrize Ltd has a 12-month low of $35.78 and a 12-month high of $65.94.
Amrize (NYSE:AMRZ – Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported $1.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.05. Amrize had a net margin of 9.93% and a return on equity of 10.02%. The company had revenue of $3.77 billion during the quarter. During the same quarter last year, the firm posted $0.98 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, equities research analysts predict that Amrize Ltd will post 2.30 EPS for the current year.
Amrize Dividend Announcement
The firm also recently declared a dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Tuesday, November 10th will be paid a dividend of $0.11 per share. The ex-dividend date is Tuesday, November 10th. Amrize’s dividend payout ratio (DPR) is currently 4.98%.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on AMRZ. Barclays lowered their price objective on shares of Amrize from $55.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, October 19th. Deutsche Bank cut their target price on shares of Amrize from $64.00 to $56.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. Oppenheimer decreased their target price on shares of Amrize from $55.00 to $52.00 and set an “outperform” rating for the company in a research note on Monday, November 2nd. William Blair set a $40.00 price target on Amrize in a report on Wednesday, September 2nd. Finally, DA Davidson increased their price target on Amrize from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, October 30th. Eight analysts have rated the stock with a Buy rating, seven have issued a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, Amrize has an average rating of “Hold” and a consensus price target of $46.96.
Check Out Our Latest Report on AMRZ
Amrize Profile
Amrize is a North American building materials and construction solutions company serving customers across the United States and Canada. Its operations span the construction materials and building envelope markets. The company supplies cement, aggregates, ready-mix concrete and asphalt, as well as roofing and other building-envelope products and services. These materials and solutions support residential, commercial and infrastructure projects. Amrize became an independent publicly traded company in 2025 through the spin-off of Holcim’s North American business.
Featured Stories
- Five stocks we like better than Amrize
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding AMRZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amrize Ltd (NYSE:AMRZ – Free Report).
Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.
